The BCR-ABL fusion gene is highly unstable in these primitive CML cells, and it is associated with frequent genetic alterations and mutations in BCR-ABL itself as well as in other genes such as p53 even in the absence of imatinib exposure [30]. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.